 |
|
alpha-1,3-galactosyltransferase-expressing allogeneic lung tumor cell vaccine
An allogeneic lung cancer vaccine with potential immunostimulating and antineoplastic activities. Derived from allogeneic lung tumor cells, alpha-1,3-galactosyltransferase-expressing allogeneic lung tumor cell vaccine is engineered to express the murine alpha-1,3-galactosyltransferase (GalT), an enzyme humans lack. GalT catalyzes the expression of foreign alpha-1,3-galactosyl (alpha-gal) carbohydrate epitopes in glycoproteins and in glycolipids on the cell membranes of the allogeneic lung tumor cells present in the vaccine, essentially producing a "xenograft". The hyperacute rejection involves pre-existing human anti-alpha-gal antibodies that bind the foreign alpha-gal epitopes expressed by the vaccine tumor cell “xenograft”, resulting in complement-mediated cytotoxicity (CMC) and antibody-dependent cell-mediated cytotoxicity (ADCC) towards endogenous lung tumor cells with unmodified carbohydrate epitopes. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| US brand name: | | HyperAcute-Lung Cancer Vaccine | | |
| Previous: | allopurinol, aloe vera gel, Aloxi, alpha fetoprotein adenoviral vector vaccine, alpha fetoprotein plasmid DNA vaccine | | Next: | alpha-1,3-galactosyltransferase-expressing allogeneic pancreatic tumor cell vaccine, alpha-Gal glycosphingolipids, alpha-galactosylceramide-pulsed autologous dendritic cells, alprazolam, alprostadil |
|
|
